PBAC Public Summary Documents – May 2024

Page last updated: 1 October 2024

Public Summary Documents relating to the May 2024 PBAC meeting.

• Aflibercept (CNV): Solution for intravitreal injection 11.34 mg in 100 microlitres (114.3 mg per mL); Eylea®
• Aflibercept (DMO): Solution for intravitreal injection 11.34 mg in 100 microlitres (114.3 mg per mL); Eylea®
• Foslevodopa with foscarbidopa: Solution for subcutaneous infusion foslevodopa 2400 mg with foscarbidopa 120 mg in 10 mL; Vyalev®

The following Public Summary Document has been updated:

March 2024 PBAC meeting

• Migalastat: Capsule containing migalastat hydrochloride 150 mg; Galafold®
• Respiratory syncytial virus vaccine: Injection (0.5 mL); Abrysvo®